UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Using index funds for stock diversification can simplify your investment strategy. Explore how they can provide broad market exposure.
23,126 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
A fresh look at HAIN's Q3 2026 earnings and what it means for investors. Learn the metrics that matter, how to read t...
Investors are rethinking where to place bets as AI hype cools. Transportation stocks offer diversification and exposu...
A SpaceX rumor about a full tech stack tied to Apple investor impact sparked a volatile session for AAPL, even as Elo...
Canaccord Genuity lowers AeroVironment's target to $330 but preserves a Buy rating, underscoring long-term optimism a...
Gate teams up with Alpaca to offer real stock trading to users worldwide, bridging crypto and traditional markets wit...
As Boyd Gaming nears its July 23 earnings, traders are weighing a potential 17.2% upside fueled by a disciplined buyb...
Tariff headlines grab attention, but everyday shopping never stops. This guide highlights two tariff-proof retail sto...
Rubrik faces a pivotal Q1 print, with traders watching for signs of margin expansion and cash flow improvement after ...
Investors are eyeing a renewed push for a classic dividend king as a robust oncology portfolio and resilience in earn...
A major hydration company with billion-dollar revenue just welcomed a new investor stake, sending shares higher. This...
Amgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...